Advertisements

Esomeprazol Mylan

Quick links to important sections

Esomeprazol Mylan

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Esomeprazol Mylan

Esomeprazol Mylan is a synthetic prescription-only medicine classified as a Proton Pump Inhibitor (PPI). Its core function is to reduce the amount of acid produced by the stomach, providing relief from conditions related to excessive gastric acid secretion.

Property Description
Active ingredient Esomeprazole (typically as magnesium trihydrate)
Form Gastro-resistant tablet or delayed-release capsule
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Suppression of gastric acid secretion
Origin Synthetic substituted benzimidazole

What Type of Medicine is Esomeprazol Mylan?

The active compound in Esomeprazol Mylan, a preparation from the pharmaceutical company Mylan, is esomeprazole, which belongs to the class of substituted benzimidazoles. This specific drug is differentiated within the PPI class because its active part is the isolated S-enantiomer of omeprazole. This unique chemical configuration is clinically recognized for contributing to a more effective degree of acid control. This formulation is typically prescribed for adults and young people aged 12 years and above, which reflects its specific regulatory authorization for a broad patient group.


Composition and Essential Form

The essential composition utilizes esomeprazole in the form of a gastro-resistant tablet or delayed-release capsule. This formulation is crucial for its proper function because esomeprazole is highly unstable in low pH environments. This protective enteric coating is necessary to allow the active ingredient to pass safely through the stomach and dissolve in the small intestine. The primary purpose of this design is to ensure the drug reaches the parietal cells intact to execute its main general purpose: the controlled, long-term suppression of gastric acid secretion. This reduction in acidity is used to ease discomfort and promote healing in the esophagus due to acid reflux.

Advertisements

What side effects are possible with Esomeprazol Mylan?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Esomeprazol Mylan (esomeprazole), strictly based on government regulatory labeling, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).

Side effects are categorized by frequency and the body system affected:

Classification Examples of Adverse Reactions (by System)
Common (ge 1/100 to < 1/10) Nervous System: Headache. Gastrointestinal: Abdominal pain, flatulence, nausea, vomiting, constipation, diarrhea.
Uncommon (ge 1/1,000 to < 1/100) Skin: Dermatitis, rash, pruritus. Nervous System: Dizziness, insomnia. Hepatobiliary: Elevated liver enzymes.

Serious Adverse Reactions are rare but officially documented, and include severe hypersensitivity reactions (e.g., angioedema), severe cutaneous adverse reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), and blood disorders like agranulocytosis.

Safety Considerations and Constraints

The regulatory profile highlights specific safety patterns related to exposure duration:

  • Adverse effects such as headache and common gastrointestinal disturbances are generally more common at the start of treatment.
  • The risk of hypomagnesemia (low magnesium levels) and increased risk of bone fracture (hip, wrist, or spine) are associated with prolonged use, typically defined as exceeding one year.
  • The medication is contraindicated in patients with known hypersensitivity to the active substance or any substituted benzimidazoles. Caution is mandated in patients with severe hepatic impairment.
Advertisements

Overdose and Emergency Response

The official regulatory documents state that experience with Esomeprazol Mylan (esomeprazole) overdose in humans is limited, and specific treatment recommendations cannot be given. The available data from a high-dose ingestion case (280 mg) documented symptoms that were transient and included weakness, loose stools, and nausea. Single doses up to 80 mg have been reported as uneventful, suggesting a low acute toxicity profile in the context of these specific ingestion amounts.


When to Seek Immediate Medical Help

It is mandatory to seek immediate medical attention for any suspected overdose involving this medication. This requirement stems from the need for professional evaluation and the limited human clinical data available on the effects of extreme overdose. The regulatory profile mandates that urgent care be sought to ensure clinical signs are managed and vital functions are supported.


Management and Treatment Procedures

No specific antidote is known for esomeprazole overdose. Therefore, treatment is explicitly required to be symptomatic and supportive. As a procedural finding relevant to clinical management, Esomeprazole is extensively protein-bound and is thus not readily dialyzable.

Advertisements

Therapeutic Uses of Esomeprazol Mylan

This medication is commonly used to help manage conditions linked to excessive stomach acid.


Easing Symptoms of Acid Reflux and Healing Esophageal Damage

This medication is primarily relevant for managing symptom clusters that may become intense or disruptive, focusing on providing symptomatic relief from disruptive heartburn and frequent acid regurgitation associated with Gastroesophageal Reflux Disease (GERD). It is applied to assist with the healing of tissue damage, such as erosive esophagitis, which contributes to improved comfort during periods of heightened symptoms and may assist with maintaining comfort and stability. The core therapeutic contexts include the healing of gastric and duodenal ulcers, reduction of ulcer recurrence risk in H. pylori eradication, and supporting the stomach lining in patients requiring necessary long-term use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

“This therapeutic effect supports the patient during difficult episodes by easing distress and supports general well-being during symptomatic phases.”

In conditions characterized by periods of heightened symptoms due to extreme acid overproduction, such as Zollinger-Ellison Syndrome, the medication is considered relevant for easing the overall symptom burden. It may help patients cope more steadily with symptom fluctuations when symptoms are more noticeable.

Symptom Focus: Heartburn and Acid Regurgitation

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Esomeprazol Mylan?

Eligibility for Esomeprazol Mylan is strictly defined by regulatory authorities based on contraindications, age, and specific health conditions.

Absolute Contraindications

Esomeprazol Mylan is contraindicated and must not be used in the following populations, as stated in official labeling:

  • Patients with documented hypersensitivity (allergy) to esomeprazole, any of the formulation's excipients, or to the class of drugs known as substituted benzimidazoles (which includes other PPIs).
  • Patients who are concurrently receiving certain antiretroviral medicines, including nelfinavir or rilpivirine-containing products.

Age-Based and Conditional Eligibility

Population Group Eligibility Status Restriction/Limitation
Adults & Adolescents Established use (ge 12 years) Standard eligibility for approved uses.
Children & Infants Established use (ge 1 month old) Safety and efficacy are not established for infants younger than 1 month of age.
Older Adults Established use No mandatory dosage adjustment is required based on age alone.
Severe Liver Impairment Restricted use A maximum dose of 20 mg/day should not be exceeded.
Pregnancy/Lactation Not Recommended Use is generally not recommended; the decision to use during pregnancy or lactation should be approached with caution.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information regarding Esomeprazol Mylan interactions is primarily structured around its effect on gastric acidity and its metabolism by liver enzymes.

Contraindicated Combinations

Co-administration with certain medicinal products is explicitly prohibited or strongly discouraged by regulatory bodies. This includes the antiretrovirals Nelfinavir and Rilpivirine-containing products due to the significant risk of reduced plasma concentrations of the co-administered drug.

Pharmacokinetic Interactions

1. Acidity-Dependent Absorption

As a proton pump inhibitor, Esomeprazol Mylan changes the internal stomach environment. This officially leads to decreased systemic exposure for medicinal products that require an acidic pH for absorption, such as Atazanavir, Ketoconazole, and Erlotinib. Conversely, it may increase the systemic exposure of other substances, such as Digoxin.

2. CYP Enzyme Modulation

The drug is an inhibitor of the liver enzyme CYP2C19. This inhibition is the basis for the regulatory caution to avoid co-administration with the antiplatelet medicine Clopidogrel, as it reduces the formation of its active metabolite. Monitoring is also required when co-administering with Warfarin due to officially reported changes in INR values. Concomitant use with CYP inducers like Rifampin or the herbal product St. John's Wort is avoided as they substantially reduce Esomeprazole plasma concentrations.

Procedural Constraints

Esomeprazol Mylan must be temporarily discontinued (typically 14 days) before measuring Chromogranin A (CgA) levels, as the drug may interfere with the diagnostic investigation.

Advertisements

Mechanism of Action

How Esomeprazol Mylan Works

Esomeprazol Mylan is a Proton Pump Inhibitor (PPI) that provides a specific pathway for inhibiting acid production by targeting the final step in the parietal cells. This precise mechanistic focus results in an extended duration of acid inhibition.


Targeted Inhibition of the Gastric Proton Pump

This mechanism outlines the drug's action on the H^+/ K^+-ATPase enzyme, the central target that actively transports acid into the stomach. Esomeprazol is first converted into an active metabolite within the highly acidic environment of the parietal cells. This active form then forms an irreversible, covalent bond with the proton pump. This irreversible blockage stops the exchange of hydrogen ( H^+) and potassium ( K^+) ions, directly preventing the secretion of hydrochloric acid ( HCl). The mechanistic consequence is a sustained inhibition of HCl secretion.


Sustained Modulation of Gastric Secretion

The characteristic of irreversible binding means the inhibitory effect persists beyond the circulating drug's half-life, as the body must synthesize and insert new enzyme molecules to restore acid production. This mechanism establishes a continuous antisecretory state. The inhibition contributes to an elevation of the stomach pH level over a 24-hour period. The resulting physiological consequence is a substantial decrease in the acid concentration in the stomach, which is the primary physiological adjustment that results from the enzyme inactivation.

Advertisements

Dosage and Administration Information

The administration of Esomeprazol Mylan follows established parameters addressing the route, timing, frequency, and preparation constraints.

Administration Guidance

Feature Protocol
Route of Administration Oral (delayed-release forms) or Intravenous (IV) injection/infusion when oral intake is not feasible.
Standard Dosing Schedule Standard adult dose is typically 20 mg or 40 mg once daily. For pathological hypersecretory conditions, the regimen starts at 40 mg twice daily.
Timing in Relation to Meals Oral delayed-release forms must be taken at least one hour before a meal to maintain the integrity of the gastro-resistant coating and ensure proper absorption.
Swallowing Constraint The capsule or tablet must be swallowed whole with liquid; it must not be crushed, chewed, or split.
Dose for Hepatic Impairment For patients with severe hepatic impairment (Child-Pugh Class C), the maximum daily dose must not exceed 20 mg.

Procedural Structure

Standardized dosing patterns are predominantly once daily for most short-term (4 to 8 weeks) and maintenance phases (up to 6 months). If a dose is missed, it should be taken as soon as it is remembered, unless it is nearly time for the next dose, in which case the missed dose is skipped. The requirement to not manipulate the oral dosage form ensures the medicine is released past the acidic environment of the stomach, as required by the formulation.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Esomeprazol Mylan

Evidence for Healing and Maintaining Esophageal Tissue Damage

The research for esomeprazole primarily involved Randomized Controlled Trials (RCTs), a common design used for evaluating how symptoms change over time. These trials were applied in settings examining patients with erosive esophagitis—a condition linked to inflammatory or irritative states that causes damage to the tissue lining of the esophagus. Studies monitored outcomes related to physical discomfort and outcomes related to the healing of this tissue damage.

Findings describe patterns observed in these studies, where esomeprazole was studied for measurements of healing when compared against a placebo. While some comparative studies described patterns indicating differences in measurements of healing when compared to other standard PPIs, the long-term clinical significance of these differences is not fully established. Research for the most advanced stages of tissue damage remains limited.


Evidence for Short-Term Symptom Management (GERD)

Esomeprazole was also evaluated in research exploring short-term symptom changes for patients with reflux symptoms, including those without visible tissue damage (Non-Erosive Reflux Disease, or NERD). These short-term Randomized Controlled Trials tracked patient-reported outcomes describing perceived discomfort such as heartburn and acid regurgitation.

Research highlights changes measured during these short-term studies, reporting on the measured rate of symptom resolution over two to four weeks when esomeprazole was compared against placebo. Comparative studies examined symptom patterns in the observed populations against other PPIs.

Uncertainty remains when assessing consistent differences in symptom outcomes. High-quality comparative studies have not consistently reported that esomeprazole provided differences in symptom resolution when compared to other standard-dose PPIs in the NERD population. Follow-up durations were limited, providing research that mainly explores short-term symptom changes.


Research Exploring Ulcer Outcomes in NSAID Use

The research explored esomeprazole for two scenarios: conditions related to the presence of ulcers (gastric and duodenal) and for research exploring ulcer prevention in patients who require necessary long-term use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The evidence is drawn from Randomized Controlled Trials and extended Observational Follow-up Studies.

Studies monitored outcomes related to systemic or functional imbalance by measuring the rate of Ulcer Healing (endoscopic confirmation) over several weeks. For prevention, research monitored the Ulcer Recurrence Rate over six months to a year in patients who continued to take NSAIDs.

Key Studies & References

  1. Long-term efficacy and safety of esomeprazole in patients with Zollinger-Ellison syndrome (Phase III Open-Label Study)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Esomeprazol Mylan (FAQ)


Q: What is the main difference between Esomeprazol Mylan and other proton pump inhibitor (PPI) medications?

Esomeprazole is structurally defined as the S-isomer of omeprazole, a specific active component. This distinct chemical formulation is cited in regulatory documents as having a specific profile for inhibiting acid secretion. Official research summaries have noted that studies examining symptom relief have not consistently demonstrated differences compared to other standard PPIs for all approved uses.


Q: Is Esomeprazol Mylan the same as generic esomeprazole or the brand-name Nexium?

Esomeprazol Mylan is one of the available generic versions of the active ingredient esomeprazole. The original brand name for this active ingredient is Nexium. Regulatory standards dictate that generic versions contain the same active substance found in the brand-name medicine.


Q: What are the most commonly reported side effects when taking Esomeprazol Mylan?

Official product information lists common side effects, meaning they may affect 1 in 100 people or more. These generally include effects on the nervous system, such as headache, and gastrointestinal effects like nausea, vomiting, abdominal pain, diarrhea, and constipation.


Q: What is the difference in chemical structure between esomeprazole and omeprazole?

The official designation for esomeprazole is the S-enantiomer, which is a specific form of omeprazole. This unique structure defines it chemically as an isolated, single isomer. This structure is linked to specific characteristics in how the body processes the medication.


Q: Why might a doctor switch a patient from Omeprazole to Esomeprazol Mylan?

The unique S-enantiomer structure of esomeprazole can lead to specific characteristics in how the medicine is processed by the body compared to omeprazole. This difference, along with results from studies on measured acid control, may be factors a prescriber considers when making a decision about treatment.


Q: Is it true that certain side effects like fatigue and nausea are more common when first starting Esomeprazol Mylan?

Official safety information notes that common adverse effects, including gastrointestinal disturbances like nausea, are generally reported to be more frequent during the initial phase of treatment. These effects often decrease as the body adjusts to the medicine.


Q: Does Esomeprazol Mylan interact with over-the-counter supplements like St. John’s Wort?

Official regulatory documents advise against taking esomeprazole with the herbal product St. John’s Wort. This combination should be avoided because St. John’s Wort may cause a substantial reduction in the amount of esomeprazole circulating in the blood.


Q: Is it true that taking Esomeprazol Mylan can cause a skin rash that is sensitive to sunlight?

Official side effect reports list dermatitis and rash as uncommon effects. Furthermore, regulatory documents note that severe skin reactions, including those related to lupus which can appear as a rash in sun-exposed areas, have been reported with the use of PPIs.


Q: Why might long-term use of Esomeprazol Mylan require a doctor to check blood work?

Regulatory documents indicate that prolonged use, generally defined as exceeding one year, is associated with a reported risk of developing low magnesium levels (hypomagnesemia). For this reason, official information suggests that monitoring of magnesium levels may be necessary for patients on prolonged use.


Q: Is it true that Esomeprazol Mylan is metabolized differently by the body compared to its predecessor Omeprazole?

Esomeprazol is the single S-enantiomer of omeprazole. This difference in structure is the basis for specific characteristics in how the body processes the drug through metabolic pathways that may differ from omeprazole.


Q: Does Esomeprazol Mylan have a different set of interactions compared to other PPIs in general?

While all Proton Pump Inhibitors (PPIs) share certain interaction principles, esomeprazole carries specific warnings regarding its effect on a liver enzyme called CYP2C19. This enzyme inhibition is the basis for required caution when used alongside certain other medicines.


Q: How quickly does Esomeprazol Mylan start to reduce stomach acid?

Official patient information describes that a reduction in the production of stomach acid generally begins within hours after the first dose. While some people may experience symptom improvement within days, achieving the full intended effect of the medicine may take up to four weeks.


Q: Is there a link between long-term use of PPIs like Esomeprazol Mylan and the development of stomach polyps?

Official regulatory documents state that extended treatment with PPIs, including esomeprazole, may be associated with an increased risk of developing fundic gland polyps. These polyps are generally described as benign (non-cancerous).


Q: Is Esomeprazol Mylan a treatment for Helicobacter pylori (H. pylori)?

Yes, esomeprazole is officially indicated and prescribed as one component of a triple-drug therapy. It is used in combination with specific antibiotics to help eradicate H. pylori bacterial infection, particularly in patients with duodenal ulcers.


Q: Can Esomeprazol Mylan cause increased anxiety or mood changes in some people?

Official side effect reports document that rare and very rare adverse reactions may include disturbances in mood. These disturbances are reported to involve depression, feelings of confusion, and aggressive behavior.


Q: Can Esomeprazol Mylan cause a change in a person's taste perception?

Official safety information reports that an altered sense of taste, medically known as dysgeusia, is a known side effect. This may be experienced as an unusual, bad, or unpleasant taste.


Q: Is there an established link between Esomeprazol Mylan and the risk of C. difficile diarrhea?

Regulatory warnings indicate that treatment with proton pump inhibitors may be associated with a slightly increased risk of gastrointestinal infections. This includes Clostridium difficile-associated diarrhea, an infection that can cause severe gastrointestinal issues.


Q: Are there specific symptoms that warrant immediate medical attention while taking Esomeprazol Mylan?

Official regulatory documents advise seeking immediate medical attention for signs of a severe allergic reaction (e.g., swelling of the face, tongue, or throat) or a severe skin reaction. Urgent medical care is also advised for severe, persistent diarrhea.


Q: What does erosive esophagitis mean, and how does Esomeprazol Mylan treat it?

Erosive esophagitis is described in official documentation as damage or irritation to the tissue lining of the esophagus caused by acid reflux. Esomeprazole treats this by significantly reducing stomach acid production, which is the mechanism intended to support the healing of the damaged tissue.


Q: Does Esomeprazol Mylan help to prevent stomach ulcers caused by the use of NSAID medications?

Yes, official indications confirm that esomeprazole is approved and studied for use in reducing the risk of gastric (stomach) ulcers. This is specifically for patients who require continuous, long-term treatment with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).


Q: Can Esomeprazol Mylan cause symptoms like dizziness or blurred vision?

Official reports of side effects list dizziness as an uncommon effect. Furthermore, blurred vision has also been reported in rare cases from patients using the medication.


Q: What is the typical timeframe for seeing the full benefits of Esomeprazol Mylan?

While some improvements in symptoms may occur quickly, patient information from official sources indicates that the primary intended benefit of the medication may take up to four weeks to be observed.


Q: Can Esomeprazol Mylan be used to treat symptoms in people with gastritis?

Regulatory documents show that esomeprazole is indicated for use in treating acid-related conditions that involve inflammation and damage to the stomach lining. This may include aspects of gastritis (stomach lining inflammation), though it is not always a stand-alone primary indication.


Q: Is it necessary for older adults (the elderly) to use caution when taking Esomeprazol Mylan?

Regulatory documents state that no mandatory dose adjustment is required based on age alone. However, official information notes that older adults are one of the populations primarily affected by some of the long-term safety considerations, such as risks related to bone health.


Q: Are there any known effects of Esomeprazol Mylan on the kidneys with long-term use?

Yes, official safety information reports that an inflammatory condition of the kidneys, known as acute interstitial nephritis, has been reported in patients taking PPIs. If this condition develops, regulatory documents indicate that discontinuation of the medicine may be considered.


Q: What happens in the body if too much Esomeprazol Mylan is taken (overdose symptoms)?

Reports of overdose are rare according to regulatory documents. The symptoms that have been reported generally include common, non-severe gastrointestinal issues, such as nausea, diarrhea, abdominal pain, and headache.


Q: Does Esomeprazol Mylan interfere with the absorption of iron supplements?

Official documents explain that because esomeprazole significantly reduces stomach acidity, it can reduce the absorption of medicinal products, including iron salts, that require an acidic pH to dissolve and be absorbed effectively.


Q: What is the maximum time a person is generally expected to take Esomeprazol Mylan for common acid reflux?

The approved treatment duration for short-term symptomatic acid reflux is typically four weeks. Over-the-counter use is generally limited to 14 days, though long-term maintenance treatment is indicated for certain more severe, chronic conditions.


Q: Are there any specific food or beverages that should be avoided while taking Esomeprazol Mylan?

Regulatory documents do not list specific foods or beverages that must be avoided. They do state that the oral delayed-release form needs to be taken at least one hour before a meal to ensure proper absorption and effectiveness.


Q: Can Esomeprazol Mylan affect the effectiveness of oral contraceptive pills?

There is no official regulatory statement that indicates esomeprazole interferes with the effectiveness of common oral contraceptive pills, such as those containing estradiol or levonorgestrel.


Q: Can Esomeprazol Mylan be taken on an 'as needed' basis for infrequent heartburn?

Regulatory documents include an approval for esomeprazol to be used ‘as needed’ for the treatment of symptomatic gastroesophageal reflux disease (GERD) in patients who do not have erosive damage to the esophagus.

Advertisements

How should Esomeprazol Mylan be stored and disposed of?

How to Store and Dispose of Esomeprazol Mylan?

This section details the mandated storage and disposal requirements for Esomeprazol Mylan as specified in official regulatory labeling.

Storage Requirements

To preserve the medicine’s integrity, storage must adhere to strict environmental and packaging rules:

  • Temperature and Protection: The product must be stored below 25 C and protected from moisture and light by keeping the blister in the outer carton.
  • Packaging: Keep the medicine in its original package. If supplied in a bottle, the container must be kept tightly closed.
  • Stability: If supplied in a bottle, the contents must be used within 3 months after first opening.
  • Safety: It is mandatory to keep this medicine out of the sight and reach of children.

Disposal Instructions

Any unused or expired product requires specific handling, as it cannot be discarded as standard trash:

  • Procedure: Do not dispose of the medicine via wastewater or household waste. Unused product must be disposed of in accordance with local pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Esomeprazol Mylan found in:

A-Z Index: